Second quarter 2021 total revenues of $141.3 million , a 12% increase compared to 2020 Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021 Qelbree sNDA for adult ADHD submitted to the FDA SPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021

ROCKVILLE, Md. , July 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial

ROCKVILLE, Md. , May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar , President and CEO of

Qelbree™ has proven efficacy in ADHD, with improvement in symptoms as early as the first week ROCKVILLE, Md. , May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central

First quarter 2021 total revenues of $130.9 million , a 38% increase compared to 2020 Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021 Qelbree sNDA submission for adult ADHD anticipated in the third quarter of 2021 SPN-830 (apomorphine infusion pump) NDA

ROCKVILLE, Md. , May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S.p.A.

ROCKVILLE, Md. , April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md. , April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc.

ROCKVILLE, Md. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar , President and CEO of Supernus

Full year 2020 total revenues of $520.4 million , a 32% increase compared to 2019 Full year 2020 operating earnings of $173.7 million , a 17% increase compared to 2019 SPN-812 NDA assigned an early April 2021 PDUFA date Positive results from Phase III study for SPN-812 in adults with ADHD announced